When hyperinsulinaemia is already present, the hypoglycaemics, high dose insulin and insulin secreteagogues, sulphonylureas, can have the adverse effects, worsening other aspects of MetS, such as central obesity. This evidence concerns the gene INS and Abdominal obesity.